Australia markets closed

PROCEPT BioRobotics Corporation (PRCT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
35.61-1.47 (-3.96%)
At close: 1:00PM EST
33.68 -1.93 (-5.42%)
After hours: 03:18PM EST
Full screen
Trade prices are not sourced from all markets
Previous close37.08
Open36.00
Bid0.00 x 800
Ask0.00 x 800
Day's range34.50 - 36.38
52-week range33.56 - 47.73
Volume114,407
Avg. volume239,917
Market cap1.549B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-8.49
Earnings date04 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est49.00
  • Motley Fool

    PROCEPT BioRobotics Corporation (PRCT) Q3 2021 Earnings Call Transcript

    Joining me from PROCEPT BioRobotics are Reza Zadno, CEO; and Kevin Waters, CFO. Earlier today, PROCEPT released financial results for the quarter ended September 30, 2021. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

  • GlobeNewswire

    PROCEPT BioRobotics Corp. Reports Third Quarter 2021 Financial Results and Provides 2021 Revenue Guidance

    REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the quarter ended September 30, 2021. Recent Highlights Total revenue of $8.7 million for the third quarter of 2021, compared to $2.1 million in the prior year periodU.S. system revenue of $5.0 million for the third quarter of 2021, compared to

  • GlobeNewswire

    PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors

    REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors. Ms. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Intersect ENT, Inc., Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc.